Table 1.
Clinicopathologic variables and the expression of NGF and HO1 in 167 gastric carcinomas
| Characteristics | No. | NGF | HO1 | NGF/HO1 expression pattern | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive | p | Positive | p | −/− | −/+ or +/− | +/+ | p | |||
| Age, years | <60 | 50 | 11 (22%) | 0.002 | 18 (36%) | 0.012 | 30 (60%) | 11 (22%) | 9 (18%) | <0.001 |
| ≥60 | 117 | 56 (48%) | 67 (57%) | 30 (26%) | 51 (44%) | 36 (31%) | ||||
| Sex | Female | 41 | 12 (29%) | 0.103 | 34 (83%) | <0.001 | 7 (17%) | 22 (54%) | 12 (29%) | 0.009 |
| Male | 126 | 55 (44%) | 51 (40%) | 53 (42%) | 40 (32%) | 33 (26%) | ||||
| CEAa | Normal | 107 | 40 (37%) | 0.358 | 56 (52%) | 0.232 | 39 (36%) | 40 (37%) | 28 (26%) | 0.944 |
| Elevated | 30 | 14 (47%) | 12 (40%) | 11 (37%) | 12 (40%) | 7 (23%) | ||||
| CA19-9a | Normal | 121 | 47 (39%) | 0.392 | 60 (50%) | 0.975 | 44 (36%) | 47 (39%) | 30 (25%) | 0.843 |
| Elevated | 16 | 8 (50%) | 8 (50%) | 5 (31%) | 6 (38%) | 5 (31%) | ||||
| Tumor stage | I & II | 77 | 27 (35%) | 0.218 | 34 (46%) | 0.107 | 33 (43%) | 27 (35%) | 17 (24%) | 0.189 |
| III & IV | 90 | 40 (44%) | 51 (55%) | 27 (30%) | 35 (39%) | 28 (31%) | ||||
| Tumor invasion | EGC | 33 | 10 (30%) | 0.199 | 16 (48%) | 0.757 | 15 (45%) | 10 (30%) | 8 (24%) | 0.435 |
| AGC | 134 | 57 (43%) | 69 (51%) | 45 (34%) | 52 (39%) | 37 (28%) | ||||
| Lymph node metastasis | Absence | 57 | 18 (32%) | 0.105 | 26 (46%) | 0.325 | 25 (44%) | 20 (35%) | 12 (21%) | 0.256 |
| Presence | 110 | 49 (45%) | 59 (54%) | 35 (32%) | 42 (38%) | 33 (30%) | ||||
| Venous invasion | Absence | 137 | 53 (39%) | 0.419 | 71 (52%) | 0.609 | 51 (37%) | 48 (35%) | 38 (28%) | 0.489 |
| Presence | 30 | 14 (47%) | 14 (47%) | 9 (30%) | 14 (47%) | 7 (23%) | ||||
| WHO classification | Tubular | 115 | 54 (47%) | 0.011 | 65 (57%) | 0.052 | 33 (29%) | 45 (39%) | 37 (32%) | 0.010 |
| Signet ring cell | 18 | 2 (11%) | 8 (44%) | 10 (56%) | 6 (33%) | 2 (11%) | ||||
| Mucinous | 17 | 4 (24%) | 4 (24%) | 9 (53%) | 8 (47%) | 0 (0%) | ||||
| Mixed | 13 | 5 (38%) | 6 (46%) | 6 (46%) | 3 (23%) | 4 (31%) | ||||
| Papillary | 2 | 2 (100%) | 2 (100%) | 0 (0%) | 0 (0%) | 2 (100%) | ||||
| Neuroendocrine | 2 | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | 0 (0%) | ||||
| Histologic gradeb | WD | 11 | 5 (45%) | 0.326 | 7 (64%) | 0.803 | 4 (36%) | 2 (18%) | 5 (45%) | 0.433 |
| MD | 65 | 35 (54%) | 38 (58%) | 15 (23%) | 27 (42%) | 23 (35%) | ||||
| PD | 41 | 16 (39%) | 22 (54%) | 14 (34%) | 16 (39%) | 11 (27%) | ||||
| Lauren classification | Intestinal | 75 | 34 (45%) | 0.010 | 44 (59%) | 0.154 | 22 (29%) | 28 (37%) | 25 (33%) | 0.226 |
| Diffuse | 71 | 20 (28%) | 33 (46%) | 32 (45%) | 25 (35%) | 14 (20%) | ||||
| Mixed | 21 | 13 (62%) | 8 (38%) | 6 (29%) | 9 (43%) | 6 (29%) | ||||
| HO1 | Negative | 82 | 22 (27%) | <0.001 | ||||||
| Positive | 85 | 45 (53%) | ||||||||
Abbreviations: EGC early gastric cancer, AGC advanced gastric cancer, WD well differentiated, MD moderately differentiated, PD poorly differentiated
aThe data for the serum levels of CEA and CA19-9 were available in 137 and 137 patients, respectively
bHistologic grading was carried in tubular and papillary type carcinomas according to the grading system of the WHO histological classification of gastric tumors